TOKYO (dpa-AFX) - The U.S. Food and Drug Administration has acknowledged Astellas Pharma's resubmission of the Biologics License Application (BLA) for zolbetuximab, a first-in-class investigational
Astellas Pharma Inc. announced that the U.S. Food and Drug Administration has acknowledged the company s resubmission of the Biologics License Application for zolbetuximab, a first-in-class.
Fezolinetant Safe, Effective for Moderate-to-Severe Menopause Hot Flashes neurologyadvisor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from neurologyadvisor.com Daily Mail and Mail on Sunday newspapers.
FDA Accepts BLA Resubmission for Zolbetuximab in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
Nanoform's biologics technology showcased by large pharma at drug delivery conference; Nanoenzalutamide and nanoapalutamide partnering discussions progress as planned di.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from di.se Daily Mail and Mail on Sunday newspapers.